Related references
Note: Only part of the references are listed.Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
D. Husereau et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2022)
State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
Harald Hampel et al.
ALZHEIMERS & DEMENTIA (2022)
Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment
Young-Sil Lee et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2021)
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Gerard N. Bischof et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois et al.
LANCET NEUROLOGY (2021)
Global Prevalence of Young-Onset Dementia A Systematic Review and Meta-analysis
Stevie Hendriks et al.
JAMA NEUROLOGY (2021)
Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies
Marcello Rossi et al.
ACTA NEUROPATHOLOGICA (2020)
Health Economic Decision Tree Models of Diagnostics for Dummies: A Pictorial Primer
Tamlyn Rautenberg et al.
DIAGNOSTICS (2020)
Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment
N. Falgas et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
Avinash Chandra et al.
HUMAN BRAIN MAPPING (2019)
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Daniel Alcolea et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies
Matilde Bongianni et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
Raphael Wittenberg et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia
Ron L. H. Handels et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Giovanni B. Frisoni et al.
LANCET NEUROLOGY (2017)
Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease
Spencer A. W. Lee et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir
John Hornberger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study
Marina Boccardi et al.
JAMA NEUROLOGY (2016)
Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease
Cristina Valcarcel-Nazco et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Biomarker Modeling of Alzheimer's Disease
Clifford R. Jack et al.
NEURON (2013)
Nonamnestic Presentations of Early-Onset Alzheimer's Disease
Mario F. Mendez et al.
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes
David L. Weimer et al.
ALZHEIMERS & DEMENTIA (2009)
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola et al.
ARCHIVES OF NEUROLOGY (2009)
CSF biomarker levels in early and late onset Alzheimer's disease
Femke H. Bouwman et al.
NEUROBIOLOGY OF AGING (2009)
Additional Patient Outcomes and Pathways in Evaluations of Testing
Patrick M. M. Bossuyt et al.
MEDICAL DECISION MAKING (2009)
Share Paper
